Genitourinary Drugs Market – By Drug Type (Hormonal Therapy {Androgen, Estrogen}, Anti-infectives), Application (Urinary Tract Infections, Prostate Cancer), Route of Administration (Oral, Parenteral), Distribution Channel – Global Forecast, 2024­2032

Genitourinary Drugs Market Size

Genitourinary Drugs Market size was valued at USD 28.7 billion in 2023 growing at a CAGR of 2.3% between 2024 and 2032. The key factors driving the growth of the market include the increasing prevalence of genitourinary disorders, such as urinary tract infections (UTIs). UTIs are among the most common infections in women, and their high incidence rate is driving the demand for effective anti-infective medications, which boosts market growth.
 

For instance, according to an article published by the National Institutes of Health, it has been reported that between 24% and 45% of women in the U.S. report urinary incontinence. Women between the ages of 20 and 39 experience some degree of incontinence between 7% and 37%, while women over 60 report daily incontinence between 9% and 39%.
 

Additionally, the growing elderly population, particularly in developed countries, leads to a higher prevalence of benign prostatic hyperplasia (BPH), necessitating treatment options like alpha-blockers and hormonal therapies. This trend is anticipated to foster market growth.
 

Genitourinary tract agents are medications used to treat conditions of the reproductive organs and the excretory or urinary tract. They address a range of issues, including reproductive and urinary tract infections, congenital abnormalities, cancers of the urological and reproductive systems, and sexual dysfunction.  
 

Genitourinary Drugs Market Trends

The development of innovative and improved hormonal therapies, offering more effective and safer options, is driving market growth. Recent advancements in oncology, particularly the development of prostate cancer therapeutics, are significantly influencing the market for genitourinary cancer drugs. For instance, in March 2024, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab), in combination with cisplatin and gemcitabine, for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC). This strategy is expected to enhance the company’s competitive position and market reach. Furthermore, the development and approval of new drugs for genitourinary disorders, such as overactive bladder treatment, are expanding therapeutic options. This expansion is anticipated to contribute to the growth of the market.

Genitourinary Drugs Market Analysis

Based on the drug type, the market is classified into hormonal therapy, anti-infectives, and other drug types. The hormonal therapy is further bifurcated into androgen, estrogen, and other hormonal therapy. The anti-infective segment is sub-segmented into antibiotics, antifungals, and antivirals. The hormonal therapy segment dominated the market with revenue of USD 13.8 billion in 2023.
 

• Hormonal therapy is a primary treatment for advanced prostate cancer, often relying on androgen deprivation therapy (ADT) to reduce testosterone levels. The rising incidence of prostate cancer globally is driving the demand for hormonal therapies.
   
• Moreover, the development of long-acting depot formulations, which allow for less frequent dosing, enhances patient compliance and treatment outcomes, further driving market growth.
   
• In addition, the risk of hormone-related genitourinary disorders, such as prostate cancer and benign prostatic hyperplasia (BPH), increases with age. With the global aging population, there is a corresponding rise in demand for hormonal therapies to manage these conditions, contributing to market growth.
   

Based on the application, the genitourinary drugs market is segmented into urinary tract infections, benign prostatic hyperplasia, prostate cancer, overactive bladder, bladder cancer, and other applications. The urinary tract infections segment dominated the market with market share of 31.2% in 2023.
 

• Increased awareness of the symptoms and complications of UTIs through public health campaigns has led to higher diagnosis rates. Early diagnosis and treatment are critical, which boosts the demand for UTI medications and drives market growth.
   
• In addition, a significant number of patients experience recurrent UTIs, leading to repeated treatments. This high recurrence rate drives the demand for long-term and prophylactic therapies, contributing to market growth.
   

Based on the route of administration, the global genitourinary drugs market is segmented into oral, parenteral, and topical. The oral segment dominated the market and is expected to reach USD 18.8 billion by 2032.
 

• Oral drugs are generally preferred by patients due to their non-invasive nature and the ease of administration compared to injections or other forms. This preference significantly drives the demand for orally administered genitourinary drugs.
   
• In addition, technological advancements in drug formulation have improved the bioavailability of oral drugs, making them more effective in treating genitourinary conditions. This enhancement increases the appeal of oral drugs compared to other routes of administration.
   

Based on distribution channel, the genitourinary drugs market is classified into hospital pharmacies, drug store & retail pharmacies, and online pharmacies. The hospital pharmacies segment is expected to exhibit 2.5% CAGR between 2024-2032.
 

• Hospital pharmacies play a critical role in managing complex genitourinary disorders, such as prostate cancer, severe urinary tract infections, and advanced kidney diseases. These conditions often require specialized medications that are more readily available in hospital settings.
   
• Moreover, hospital pharmacies are better equipped to monitor drug adherence and patient outcomes, especially for chronic genitourinary conditions. This capability leads to improved patient management and drives demand for their services, thereby fostering market growth.
   

North America genitourinary drugs market is expected to grow at 2.1% CAGR, to reach USD 15.4 billion by the end of 2032.
 

• The U.S. market in North America is a significant segment of the pharmaceutical industry, driven by a high prevalence of genitourinary disorders, advanced healthcare infrastructure, and ongoing research and development.
   
• In addition, the increasing incidence of lifestyle-related disorders, such as obesity and diabetes, is linked to a rise in genitourinary conditions, further fueling market growth.
   
• Furthermore, regulatory approvals by the U.S. Food and Drug Administration (FDA) play a crucial role in shaping the market landscape, with new drug approvals contributing to the expansion of treatment options.
   

UK to experience the significant growth rate in the European market.
 

• The UK's genitourinary drugs market in Europe is an evolving sector, marked by a robust healthcare system, a strong regulatory framework, and ongoing advancements in medical research. The market addresses a wide range of conditions affecting the urinary and reproductive systems, including prostate cancer, erectile dysfunction, urinary incontinence, and sexually transmitted infections (STIs).
   
• Moreover, the National Health Service (NHS) plays a pivotal role in providing access to these treatments, ensuring that a broad population base benefits from both established and innovative therapies.
   
• Furthermore, the market in the UK is influenced by several factors, including the aging population, which is driving demand for treatments related to age-associated conditions such as benign prostatic hyperplasia (BPH) and urinary incontinence.
   

The Asia Pacific genitourinary drugs market is witnessing substantial growth of 2.7% during the analysis period.
 

• The Asia Pacific market is a rapidly growing sector, driven by a combination of increasing healthcare awareness, expanding middle-class populations, and rising incidences of genitourinary disorders.
   
• Countries such as China, Japan, India, and South Korea are at the forefront of this market, which includes treatments for conditions like prostate cancer, erectile dysfunction, urinary tract infections, and sexually transmitted infections (STIs). The region's diverse healthcare landscape presents both opportunities and challenges for pharmaceutical companies.
   
• The growth of the market in Asia Pacific is propelled by demographic trends, particularly the aging populations in countries like Japan and China, where age-related conditions such as benign prostatic hyperplasia (BPH) and urinary incontinence are becoming more prevalent, driving market growth.
   

Genitourinary Drugs Market Share

The market is characterized by intense competition among key players striving to expand their market presence. Leading companies are focusing on strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their market position. These efforts aim to enhance their product and service offerings, expand their geographic reach, and invest in advanced technologies. Additionally, the market is witnessing the entry of new players, further intensifying the competitive landscape.
 

Genitourinary Drugs Market Companies

Prominent players operating in the genitourinary drugs industry are as mentioned below:

• Abbott Laboratories
• Allergan, Inc.
• AstraZeneca Plc
• Bayer AG
• Bristol-Myers Squibb Co.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline Plc
• Ionis Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Novartis AG
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd
   

Genitourinary Drugs Industry News:

• In November 2023, Astellas Pharma Inc. and Pfizer Inc. announced that the companies received the U.S. Food and Drug Administration (FDA) approval for XTANDI (enzalutamide), for the treatment of patients with nonmetastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR). This strategy is expected to improve the company’s competitive position and market reach.
   

The genitourinary drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Type

• Hormonal therapy
  • Androgen
  • Estrogen
  • Other hormonal therapy
• Anti-infective
  • Antibiotics
  • Antifungals
  • Antivirals
• Other drug types

Market, By Application

• Urinary tract infections (UTIs)
• Benign prostatic hyperplasia (BPH)
• Prostate cancer
• Overactive bladder
• Bladder cancer
• Other applications

Market, By Route of Administration

• Oral
• Parenteral
• Topical

Market, By Distribution Channel

• Hospital pharmacies
• Drug store & retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa